Dissociation of Primary and Secondary Reward-relevant Limbic Nuclei in an Animal Model of Relapse
Overview
Affiliations
The neural substrates underlying relapse to drug-seeking behavior after chronic drug abuse may differ from those underlying immediate drug-taking behavior. In a model of relapse to drug-seeking behavior following chronic cocaine self-administration and prolonged extinction, we have previously shown that rats will significantly reinstate lever responding for either primary reward (cocaine) or secondary reward (tone + light stimulus previously paired with cocaine). In the present study, we utilized reversible inactivation of discrete brain nuclei with tetrodotoxin (TTX) in order to examine the neural substrates mediating primary and secondary cocaine reward in rats allowed two weeks of cocaine self-administration. After one week of daily extinction sessions, bilateral inactivation of the basolateral amygdala resulted in significant attenuation of lever pressing for a cocaine-conditioned reward (tone + light). Following three more days of extinction, bilateral TTX inactivation of the basolateral amygdala had no effect on the reinstatement of cocaine self-administration. In contrast, TTX inactivation of the nucleus accumbens produced the exact opposite effects, with significant blockade of primary reward (cocaine alone), but not secondary reward (tone + light). Thus, cocaine-conditioned reward is neuroanatomically dissociated from primary cocaine reward.
Transcutaneous Vagus Nerve Stimulation Enhances Probabilistic Learning.
Cakir R, Buyukguduk I, Bilim P, Erdinc A, Veldhuizen M Psychophysiology. 2025; 62(3):e70037.
PMID: 40059064 PMC: 11891121. DOI: 10.1111/psyp.70037.
The prediction of market-level food choices by the neural valuation signal.
Kislov A, Shestakova A, Ushakov V, Martinez-Saito M, Beliaeva V, Savelo O PLoS One. 2023; 18(6):e0286648.
PMID: 37267322 PMC: 10237376. DOI: 10.1371/journal.pone.0286648.
Hauser S, Deehan Jr G, Knight C, Waeiss R, Engleman E, Ding Z Drug Alcohol Depend. 2023; 246:109858.
PMID: 37028106 PMC: 10212692. DOI: 10.1016/j.drugalcdep.2023.109858.
Mesa J, Carter E, Padovan-Hernandez Y, Knackstedt L Front Pharmacol. 2023; 14:1132689.
PMID: 37007027 PMC: 10060651. DOI: 10.3389/fphar.2023.1132689.
From Poison to Promise: The Evolution of Tetrodotoxin and Its Potential as a Therapeutic.
Bucciarelli G, Lechner M, Fontes A, Kats L, Eisthen H, Shaffer H Toxins (Basel). 2021; 13(8).
PMID: 34437388 PMC: 8402337. DOI: 10.3390/toxins13080517.